Skip to content

Frontlight ResearchEarly access

Trial site

Northwestern Memorial Hospital

Chicago, Illinois 60611, United StatesNot linked to an institution yet

84running trials
37closed trials

The trials here

What the 123 trials at this site are about, from their registry records.

Conditions: Lung cancer13 trials
Stroke10 trials
Atrial fibrillation7 trials
Head and neck cancer7 trials
Ovarian cancer7 trials
Melanoma6 trials
Acute myeloid leukaemia5 trials
Childhood cancers5 trials
Colorectal cancer5 trials
Glioblastoma5 trials
Multiple sclerosis5 trials
Pancreatic cancer5 trials
and 53 more
Phase: Phase 330 trials
Phase 222 trials
Phase 112 trials
Phase 1/28 trials
Phase 46 trials
Phase 2/35 trials
Status: Recruiting41 trials
Active, not recruiting35 trials
Completed28 trials
Terminated8 trials
Enrolling by invitation4 trials
Not yet recruiting4 trials
Suspended2 trials
Withdrawn1 trial
Lead sponsor: Northwestern University15 trials
Abbott Medical Devices6 trials
Pfizer6 trials
Hoffmann-La Roche4 trials
United Therapeutics4 trials
and 65 more

Running trials

Recruiting
Ocrevus Zunovo for MS: Mixed Methods
NCT07710105· Northwestern University· Source
Contact: Dylan Rice, B.A.
Recruiting
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
NCT07446322· Phase 2· Oncolytics Biotech· Source
Contact: Name: Reference Study ID Number: REO 033
Recruiting
The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI
NCT07479433· HeartFlow, Inc.· Source
Contact: Daniel Schimmel, MD
Enrolling by invitation
Estimating Insulin Sensitivity in Pregnancies With Type 1 Diabetes
NCT07351318· University of Virginia· Source
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· Phase 3· Eli Lilly and Company· Source
Contact: William Gradishar (principal investigator)
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383· Vascutek Ltd.· Source
Contact: Principal Investigator
Enrolling by invitation
Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED
NCT06944353· Northwestern University· Source
Recruiting
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
NCT07225361· Phase 4· Northwestern University· Source
Contact: Caroline Gebczak, B.S.
Recruiting
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT07207148· Northwestern University· Source
Contact: Dylan Rice, BA
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· Phase 3· Novartis Pharmaceuticals· Source
Contact: Caroline Gebczak
Recruiting
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
NCT07206225· Phase 1· Pfizer· Source
Recruiting
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
NCT06878560· Phase 1/2· United Therapeutics· Source
Recruiting
BoxX-NoAF Clinical Trial
NCT06989775· AtriCure, Inc.· Source
Contact: Meredith Chappell
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Contact: Emma Barber (principal investigator)
Active, not recruiting
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
NCT07033481· Phase 2· EIP Pharma Inc· Source
Recruiting
XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)
NCT06895070· XVIVO Perfusion· Source
Contact: Allison Mossell
Recruiting
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
NCT06552169· Phase 2· Singulera Therapeutics Inc.· Source
Contact: M. Javeed Ansari, MD, MRCP (principal investigator)
Recruiting
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591· Phase 1/2· Tango Therapeutics, Inc.· Source
Contact: Bilal Anouti, MD (principal investigator)
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531· Phase 3· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development Inc.
Recruiting
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
NCT07227246· Phase 3· Joseph Broderick, MD· Source
Contact: Babak S. Jahromi, MD, PhD
Active, not recruiting
TECTONIC CAD IVL IDE Study
NCT06885177· Abbott Medical Devices· Source
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544· Phase 1/2· Tango Therapeutics, Inc.· Source
Contact: Ditte Primdahl, MD (principal investigator)
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· Phase 3· NovoCure GmbH· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360· Phase 3· Incyte Corporation· Source
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774· Phase 3· Incyte Corporation· Source
Recruiting
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
NCT06359041· Phase 1/2· Cabaletta Bio· Source
Contact: Kaitlin King
Recruiting
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
NCT06581406· Phase 2/3· Replimune, Inc.· Source
Contact: Sunandana Chandra, MD, MS
Active, not recruiting
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141· Phase 3· Longboard Pharmaceuticals· Source
Active, not recruiting
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394· Phase 3· Longboard Pharmaceuticals· Source
Active, not recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279· Phase 3· argenx· Source
Active, not recruiting
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441· Phase 3· Gilead Sciences· Source
Active, not recruiting
Diabetes Toolkit at Discharge
NCT05663931· Northwestern University· Source
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180· Phase 3· Replimune, Inc.· Source
Contact: Sunandana Chandra, MD (principal investigator)
Recruiting
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
NCT06328777· Phase 2/3· Cabaletta Bio· Source
Contact: Kaitlin King
Active, not recruiting
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
NCT06336291· Phase 2· Philogen S.p.A.· Source
Active, not recruiting
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
NCT06192758· Boston Scientific Corporation· Source
Recruiting
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06297226· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source
Contact: Seema Singhal, Site 0005
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
NCT06121297· Phase 1/2· Cabaletta Bio· Source
Contact: Kaitlin King
Active, not recruiting
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
NCT05977907· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429· Cook Research Incorporated· Source
Contact: Neel Mansukhani, MD
Active, not recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· Phase 3· Summit Therapeutics· Source
Active, not recruiting
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326· Phase 2· Genentech, Inc.· Source
Recruiting
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT05990426· Northwestern University· Source
Contact: Anne Grace, PhD
Active, not recruiting
XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)
NCT05881278· XVIVO Perfusion· Source
Recruiting
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
NCT05887609· Phase 2· University of Colorado, Denver· Source
Contact: Emma Barber, MD
Recruiting
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
NCT05602363· Phase 1· Carna Biosciences, Inc.· Source
Contact: Study Cordinator
Recruiting
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
NCT05612347· Dartmouth-Hitchcock Medical Center· Source
Contact: Zack Jacobs
Recruiting
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
NCT05765812· Phase 1/2· Debiopharm International SA· Source
Contact: Debiopharm International S.A
Active, not recruiting
Knee Arthroplasty Activity Trial
NCT04107649· Brigham and Women's Hospital· Source

Showing 50 of 84.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Terminated
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591· Phase 1· SystImmune Inc.· Source
Completed
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC
NCT06637072· Phase 4· argenx· Source
Completed
RECOVER-SLEEP: Platform Protocol
NCT06404086· Phase 2· Duke University· Source
Completed
VOLT-AF IDE Clinical Study
NCT06223789· Abbott Medical Devices· Source
Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source
Completed
A Phase 1 Study of BMF-500 in Adults With Acute Leukemia
NCT05918692· Phase 1· Biomea Fusion Inc.· Source
Completed
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
NCT05595369· Phase 2· Kanecia Obie Zimmerman· Source
Completed
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
NCT05639751· Phase 1· Prelude Therapeutics Incorporated· Source
Completed
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
NCT05483907· Phase 2· Bridge Biotherapeutics, Inc.· Source
Terminated
Oral Statins and Protection From Hearing Loss
NCT04826237· Phase 4· Northwestern University· Source
Completed
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
NCT05590585· Phase 4· Regeneron Pharmaceuticals· Source
Completed
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05585034· Phase 1· Xencor, Inc.· Source
Completed
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
NCT05523167· Phase 2/3· argenx· Source
Terminated
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
NCT05269355· Phase 2/3· PTC Therapeutics· Source
Completed
Training Swallowing Initiation During Expiration
NCT05278039· Northwestern University· Source
Terminated
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
NCT05241873· Phase 1· Blueprint Medicines Corporation· Source
Completed
ED Physical Therapy for Chronic Low Back Pain
NCT05206630· Northwestern University· Source
Completed
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Completed
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving Ocrelizumab
NCT04998851· Phase 4· Hoffmann-La Roche· Source
Withdrawn
Use of EndoFLIP and Manometry Prior to G-POEM
NCT04844190· Northwestern University· Source
Completed
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
NCT05033080· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Completed
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782· Phase 3· United Therapeutics· Source
Completed
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT04697628· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Completed
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
NCT04649359· Phase 2· Pfizer· Source
Completed
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
NCT04609566· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Terminated
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
NCT04543188· Phase 1· Pfizer· Source
Completed
P-CHAT: Comparison of Direct to Consumer Delivery Models for Hearing Devices
NCT04618315· Northwestern University· Source
Completed
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
NCT04503551· Phase 3· Hoffmann-La Roche· Source
Terminated
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
NCT03547115· Phase 1· MEI Pharma, Inc.· Source
Completed
MIND: Artemis in the Removal of Intracerebral Hemorrhage
NCT03342664· Penumbra Inc.· Source
Completed
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR
NCT07227675· Abbott Medical Devices· Source
Terminated
Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
NCT02928497· Boston Scientific Corporation· Source
Completed
AMPLATZER™ Amulet™ LAA Occluder Trial
NCT02879448· Abbott Medical Devices· Source
Completed
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
NCT02601950· Phase 2· Epizyme, Inc.· Source
Completed
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
NCT02007512· Phase 2· Pfizer· Source
Completed
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
NCT01889238· Phase 2· Pfizer· Source
Completed
Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
NCT01064440· Phase 2· Helixmith Co., Ltd.· Source

Site data: ClinicalTrials.govUpdated 14 Nov 2026

Report an error

Northwestern Memorial Hospital: trial site – Frontlight Research